Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study

Долгосрочная эффективность и безопасность талетректиниба у пациентов с ROS1-положительным немелкоклеточным раком легкого: результаты исследования фазы II TRUST-I
Yongchang Zhang, Wenfeng Chen, Caicun Zhou, Wei Li, Fei-Wu Ran, Yongchang Zhang, Huijie Fan, Qitao Yu, Feiwu Ran, Caicun Zhou, Qitao Yu
2026-04-21

ROS1-positive non-small cell lung cancerTRUST-I studylong-term efficacy and safetyphase IItaletrectinib
Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) with activity against the ROS1 G2032R resistance mutation. Initial data from the TRUST-I study (ClinicalTrials.gov identifier: NCT04395677 ) demonstrated high response rates and intracranial (IC) activity, with promising durability, in Chinese patients with advanced ROS1 + non–small cell lung cancer (NSCLC). With longer follow-up, taletrectinib continued to demonstrate high and durable response rates in both TKI-naïve and crizotinib-pretreated patients, including IC activity and promising overall survival (OS). Among 103 TKI-naïve patients who started taletrectinib at 600 mg once daily (median follow-up, 51.0 months), the objective response rate (ORR) was 90.3% (95% CI, 82.9 to 95.3), the median duration of response (DOR) and median progression-free survival (PFS) exceeded 4 years (49.7 months and 49.6 months, respectively), and median OS was not reached. Among 66 crizotinib-pretreated patients (median follow-up, 45.2 months), the ORR was 51.5%, the median DOR was 13.2 months, the median PFS was 7.6 months, and the median OS was 25.6 months. The safety profile remained consistent with prior reports, and no new safety signals were identified. Overall, taletrectinib demonstrated durable long-term efficacy and a manageable safety profile in patients with advanced ROS1 + NSCLC.
1
Taletrectinib was evaluated for long-term efficacy and safety in patients with ROS1-positive non–small cell lung cancer in the Phase II TRUST-I study.

Taletrectinib treatment in patients with ROS1-positive non–small cell lung cancer

Long-term efficacy and safety outcomes of taletrectinib in ROS1+ NSCLC patients

Publication Details
Publication Date
2026-04-21
Journal
Publisher
ISSN
Cited by
2
Access Type
Author Information
Authors
Yongchang Zhang
Wenfeng Chen
Caicun Zhou
Wei Li
Fei-Wu Ran
Yongchang Zhang
Huijie Fan
Qitao Yu
Feiwu Ran
Caicun Zhou
Qitao Yu
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%